Xenetic Biosciences, Inc. (NASDAQ:XBIO) Sees Significant Decline in Short Interest

Xenetic Biosciences, Inc. (NASDAQ:XBIO) was the target of a large decrease in short interest in January. As of January 15th, there was short interest totaling 4,870 shares, a decrease of 23.8% from the December 31st total of 6,390 shares. Based on an average daily trading volume, of 17,808 shares, the short-interest ratio is currently 0.3 days. Approximately 0.2% of the company’s stock are sold short. Approximately 0.2% of the company’s stock are sold short. Based on an average daily trading volume, of 17,808 shares, the short-interest ratio is currently 0.3 days.

Xenetic Biosciences Trading Down 4.7%

Shares of XBIO opened at $2.22 on Monday. The company’s 50 day simple moving average is $2.33 and its 200-day simple moving average is $3.03. The firm has a market cap of $5.08 million, a PE ratio of -1.08 and a beta of 2.29. Xenetic Biosciences has a 12-month low of $1.90 and a 12-month high of $13.93.

Xenetic Biosciences (NASDAQ:XBIO) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.16. Xenetic Biosciences had a negative net margin of 110.42% and a negative return on equity of 64.66%. The firm had revenue of $1.03 million during the quarter. As a group, equities research analysts forecast that Xenetic Biosciences will post -1.01 EPS for the current fiscal year.

Hedge Funds Weigh In On Xenetic Biosciences

An institutional investor recently raised its position in Xenetic Biosciences stock. Sachetta LLC boosted its stake in Xenetic Biosciences, Inc. (NASDAQ:XBIO) by 43.1% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 15,259 shares of the company’s stock after acquiring an additional 4,593 shares during the period. Sachetta LLC owned 0.99% of Xenetic Biosciences worth $60,000 as of its most recent SEC filing. 15.12% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Xenetic Biosciences in a research report on Wednesday, January 21st. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Reduce”.

Xenetic Biosciences Company Profile

Xenetic Biosciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of enhanced protein and peptide therapeutics for oncology, immunology and rare diseases. The company leverages its proprietary platforms to extend the half-life, improve the stability and optimize the delivery of biopharmaceuticals. Xenetic’s pipeline includes novel candidates designed to address unmet medical needs in solid tumors and inherited disorders.

At the heart of Xenetic’s technology portfolio are two complementary platforms: PolyXen, which employs a unique polysialylation process to prolong drug circulation and reduce immunogenicity, and Alphabody, a next-generation antibody-mimetic framework engineered for high-affinity binding to challenging targets.